Activation of the PI3K/mTOR/AKT Pathway and Survival in Solid Tumors: Systematic Review and Meta-Analysis
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Aberrations in the phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR)/AKT pathway are common in solid tumors. Numerous drugs have been developed to target different components of this pathway. However the prognostic value of these aberrations is unclear. METHODS: PubMed was searched for studies evaluating the association between activation of the PI3K/mTOR/AKT pathway (defined as PI3K mutation [PIK3CA], lack of phosphatase and tensin homolog [PTEN] expression by immunohistochemistry or western-blot or increased expression/activation of downstream components of the pathway by immunohistochemistry) with overall survival (OS) in solid tumors. Published data were extracted and computed into odds ratios (OR) for death at 5 years. Data were pooled using the Mantel-Haenszel random-effect model. RESULTS: Analysis included 17 studies. Activation of the PI3K/mTOR/AKT pathway was associated with significantly worse 5-year survival (OR:2.12, 95% confidence intervals 1.42-3.16, p<0.001). Loss of PTEN expression and increased expression/activation of downstream components were associated with worse survival. No association between PIK3CA mutations and survival was observed. Differences between methods for assessing activation of the PI3K/mTOR/AKT pathway were statistically significant (p = 0.04). There was no difference in the effect of up-regulation of the pathway on survival between different cancer sites (p = 0.13). CONCLUSION: Activation of the PI3K/AKT/mTOR pathway, especially if measured by loss of PTEN expression or increased expression/activation of downstream components is associated with poor survival. PIK3CA mutational status is not associated with adverse outcome, challenging its value as a biomarker of patient outcome or as a stratification factor for patients treated with agents acting on the PI3K/AKT/mTOR pathway.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000100 · Cited by 28,164 · cited 1×
“This analysis was conducted in line with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines [17].”
MethodSlamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · cited 1×
“Examples of this are trastuzumab for HER2 over-expressing or amplified breast and gastric cancer [2,3], imatinib for chronic myeloid leukemia (CML) [4], vemurafenib for metastatic melanoma with (V600E) B-RAF mutations and crizotinib for non-small cell lung cancer patients with anaplastic lymphoma kinase (ALK) rearrang…”
BackgroundImproved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Bang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61121-x · Cited by 7,302
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M., Baehner, F. L., Walker, M. G., Watson, D., Park, T., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041588 · Cited by 6,277
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785 · cited 1×
“The fact that PTEN is a major regulator of the activation of the PI3K pathway could explain its association with worse outcome [19,20] as those tumors with loss of PTEN expression could have activation of the different components of this pathway.”
BackgroundAnaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y.-J., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S.-H. I., Dezube, B. J., Jänne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,446 · cited 1×
“Examples of this are trastuzumab for HER2 over-expressing or amplified breast and gastric cancer [2,3], imatinib for chronic myeloid leukemia (CML) [4], vemurafenib for metastatic melanoma with (V600E) B-RAF mutations and crizotinib for non-small cell lung cancer patients with anaplastic lymphoma kinase (ALK) rearrang…”
BackgroundTemsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
Hudes, G., Carducci, M., Tomczak, P., Dutcher, J., Figlin, R., Kapoor, A., Staroslawska, E., Sosman, J., McDermott, D., Bodrogi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066838 · Cited by 3,647 · cited 1×
“Inhibition of mTOR with rapalogs has shown clinical efficacy against some solid tumors, including everolimus for angiomyolipoma associated with tuberous sclerosis, metastatic renal cell carcinoma, breast cancer, or pancreatic neuroendocrine carcinomas and temsirolimus for renal cell carcinoma [11–14].”
BackgroundO'Brien, S. G., Guilhot, F., Larson, R. A., Gathmann, I., Baccarani, M., Cervantes, F., Cornelissen, J. J., Fischer, T., Hochhaus, A., Hughes, T., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022457 · Cited by 3,570
Motzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., Grünwald, V., Thompson, J. A., Figlin, R. A., Hollaender, N., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61039-9 · Cited by 3,019 · cited 1×
“Inhibition of mTOR with rapalogs has shown clinical efficacy against some solid tumors, including everolimus for angiomyolipoma associated with tuberous sclerosis, metastatic renal cell carcinoma, breast cancer, or pancreatic neuroendocrine carcinomas and temsirolimus for renal cell carcinoma [11–14].”
BackgroundEverolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863 · cited 1×
“Inhibition of mTOR with rapalogs has shown clinical efficacy against some solid tumors, including everolimus for angiomyolipoma associated with tuberous sclerosis, metastatic renal cell carcinoma, breast cancer, or pancreatic neuroendocrine carcinomas and temsirolimus for renal cell carcinoma [11–14].”
BackgroundTargeting PI3K signalling in cancer: opportunities, challenges and limitations
Engelman, J. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2664 · Cited by 2,445 · cited 3×
“Activation of this pathway can be a result of mutations in the PI3K or AKT genes, loss of phosphatase and tensin homolog (PTEN), or constitutive activation of upstream regulatory pathways such as receptor tyrosine kinases (Figure 1) [9,10].”
BackgroundProtein Tyrosine Phosphatases in the Human Genome
Alonso, A., Sasin, J., Bottini, N., Friedberg, I., Friedberg, I., Osterman, A., Godzik, A., Hunter, T., Dixon, J., & Mustelin, T. (2004) · Cell · doi:10.1016/j.cell.2004.05.018 · Cited by 1,886
The PI3K Pathway As Drug Target in Human Cancer
Courtney, K. D., Corcoran, R. B., & Engelman, J. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.3641 · Cited by 1,237 · cited 3×
“Activation of this pathway can be a result of mutations in the PI3K or AKT genes, loss of phosphatase and tensin homolog (PTEN), or constitutive activation of upstream regulatory pathways such as receptor tyrosine kinases (Figure 1) [9,10].”
BackgroundAn integrative genomic and proteomic analysis of pik3ca, pten, and akt mutations in breast cancer.
Stemke-Hale, K., Gonzalez-Angulo, A. M., Lluch, A., Neve, R. M., Kuo, W.-L., Davies, M., Carey, M., Hu, Z., Guan, Y., Sahin, A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6854 · Cited by 1,054 · cited 1×
“Stemke-Hale, K [28] PIK3CA mutations Breast Cancer Not reported”
BackgroundSawyers, C. L. (2008) · Nature · doi:10.1038/nature06913 · Cited by 983
Bissler, J. J., Kingswood, J. C., Radzikowska, E., Zonnenberg, B. A., Frost, M., Belousova, E., Sauter, M., Nonomura, N., Brakemeier, S., de Vries, P. J., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61767-x · Cited by 880 · cited 1×
“Inhibition of mTOR with rapalogs has shown clinical efficacy against some solid tumors, including everolimus for angiomyolipoma associated with tuberous sclerosis, metastatic renal cell carcinoma, breast cancer, or pancreatic neuroendocrine carcinomas and temsirolimus for renal cell carcinoma [11–14].”
BackgroundDrug discovery approaches targeting the PI3K/Akt pathway in cancer
Garcia-Echeverria, C., & Sellers, W. R. (2008) · Oncogene · doi:10.1038/onc.2008.246 · Cited by 473 · cited 2×
“This hypothesis is supported by data in breast cancer, which show little predictive value of PIK3CA with the mTOR inhibitor everolimus [15,16,25].”
BackgroundMethodPIK3CA Mutation Associates with Improved Outcome in Breast Cancer
Kalinsky, K., Jacks, L. M., Heguy, A., Patil, S., Drobnjak, M., Bhanot, U. K., Hedvat, C. V., Traina, T. A., Solit, D., Gerald, W., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0632 · Cited by 401 · cited 1×
“Kalinsky, K [27] PIK3CA mutations Breast Cancer Median 12.”
BackgroundBaselga, J., Cortés, J., Im, S.-A., Clark, E., Ross, G., Kiermaier, A., & Swain, S. M. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.5384 · Cited by 364
Lotan, T. L., Gurel, B., Sutcliffe, S., Esopi, D., Liu, W., Xu, J., Hicks, J. L., Park, B. H., Humphreys, E., Partin, A. W., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1244 · Cited by 348 · cited 1×
“Lotan, LT [37] PTEN loss Prostate Cancer Median 16.”
BackgroundAnalysing and Presenting Results
Macaskill, P., Gatsonis, C., Deeks, J. J., Harbord, R., & Takwoingi, Y. (2010) · Bristol Research (University of Bristol) · Cited by 337
AKT activation predicts outcome in breast cancer patients treated with tamoxifen
Kirkegaard, T., Witton, C. J., McGlynn, L. M., Tovey, S. M., Dunne, B., Lyon, A., & Bartlett, J. M. (2005) · The Journal of Pathology · doi:10.1002/path.1829 · Cited by 268 · cited 1×
“Kirkegaard, T [31] mTOR or AKT activation Breast Cancer Median 6.”
BackgroundPIK3CA mutations in breast cancer are associated with poor outcome
Li, S. Y., Rong, M., Grieu, F., & Iacopetta, B. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-005-9048-0 · Cited by 207 · cited 1×
“Li, SY [29] PIK3CA mutations Breast Cancer Median 4.”
BackgroundBarbareschi, M., Buttitta, F., Felicioni, L., Cotrupi, S., Barassi, F., Del Grammastro, M., Ferro, A., Dalla Palma, P., Galligioni, E., & Marchetti, A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0266 · Cited by 193 · cited 2×
“Mutations in the helical domain may favor the oncogenic capability of PIK3CA by facilitating its interaction with certain signaling intermediates linked to the transmission of pro-oncogenic signals [21].”
BackgroundCastellvi, J., Garcia, A., Rojo, F., Ruiz‐Marcellan, C., Gil, A., Baselga, J., & Ramon y Cajal, S. (2006) · Cancer · doi:10.1002/cncr.22195 · Cited by 177 · cited 2×
“However, results from these studies were heterogeneous as the markers evaluated belong to different components of the pathway (mTORC1 and mTORC2) [24].”
BackgroundResultTerakawa, N., Kanamori, Y., & Yoshida, S. (2003) · Endocrine Related Cancer · doi:10.1677/erc.0.0100203 · Cited by 161 · cited 1×
“Terakawa, N [40] PTEN loss Gynecological cancer Not reported”
BackgroundYu, G., Wang, J., Chen, Y., Wang, X., Pan, J., Li, G., Jia, Z., Li, Q., Yao, J. C., & Xie, K. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2138 · Cited by 156 · cited 1×
“Yu, G [35] mTOR or AKT activation Gastrointestinal tumors Mean 3.”
BackgroundSawai, H., Yasuda, A., Ochi, N., Ma, J., Matsuo, Y., Wakasugi, T., Takahashi, H., Funahashi, H., Sato, M., & Takeyama, H. (2008) · BMC Gastroenterology · doi:10.1186/1471-230x-8-56 · Cited by 129 · cited 1×
“Sawai, H [38] PTEN loss Gastrointestinal tumors Median 3.”
BackgroundPIK3CA Exon 20 Mutation is Independently Associated with a Poor Prognosis in Breast Cancer Patients
Lai, Y. L., Mau, B.-L., Cheng, W., Chen, H. M., Chiu, H., & Tzen, C. ‐. (2008) · Annals of Surgical Oncology · doi:10.1245/s10434-007-9751-7 · Cited by 107 · cited 1×
“Lai, Y [30] PIK3CA mutations Breast Cancer Median, 6.”
BackgroundSze, K. M., Wong, K. L.-T., Chu, G. K. Y., Lee, J. M., Yau, T.-O., & Ng, I. O. (2011) · Hepatology · doi:10.1002/hep.24232 · Cited by 91 · cited 1×
“Sze, KM [39] PTEN loss Gastrointestinal tumors Not reported”
BackgroundLi, X., Wang, Y. C., Li, W. S., & Du, Y. (2009) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-28-152 · Cited by 91
Oncogenic Targets, Magnitude of Benefit, and Market Pricing of Antineoplastic Drugs
Amir, E., Šeruga, B., Martínez‐López, J., Kwong, R. C., Pandiella, A., Tannock, I. F., & Ocaña, A. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.2393 · Cited by 74
Self-citationClinical significance of tumor suppressor PTEN in colorectal carcinoma
Hsu, C.-P., Kao, T., Chang, W., Nieh, S., Wang, H. L., & Chung, Y. C. (2010) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2010.12.003 · Cited by 70 · cited 1×
“Hsu, CP [36] PTEN loss Gastrointestinal tumors Median 4.”
BackgroundRamirez-Ardila, D. E., Helmijr, J., Look, M. P., Lurkin, I., Ruigrok-Ritstier, K., Laere, S. V., Dirix, L. Y., Sweep, F. C. G. J., Span, P. N., Linn, S. C., et al. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2529-7 · Cited by 58
Baselga, J. M., Cortés, J., Im, S., Clark, E., Kiermaier, A. C., Ross, G., & Swain, S. (2012) · Cancer Research · doi:10.1158/0008-5472.sabcs12-s5-1 · Cited by 58 · cited 1×
“and whether HER2 is over-expressed or amplified compared to HER2-normal [22,23].”
BackgroundThe evolving landscape of protein kinases in breast cancer: Clinical implications
Ocaña, A., Amir, E., Šeruga, B., Martín, M., & Pandiella, A. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.05.004 · Cited by 24 · cited 2×
“This hypothesis is supported by data in breast cancer, which show little predictive value of PIK3CA with the mTOR inhibitor everolimus [15,16,25].”
BackgroundMethodSelf-citationDong, Y., Yang, X., Wong, O. G., Zhang, X., Liang, Y., Zhang, Y., Wong, W., Nong, L., Liao, Q., & Li, T. (2011) · Human Pathology · doi:10.1016/j.humpath.2011.08.021 · Cited by 13
Cited by
Current State and Future Challenges for PI3K Inhibitors in Cancer Therapy
Sirico, M., D’Angelo, A., Gianni, C., Casadei, C., Merloni, F., & De Giorgi, U. (2023) · Cancers · doi:10.3390/cancers15030703 · Cited by 121
Kazi, A., Xiang, S., Yang, H., Chen, L., Kennedy, P., Ayaz, M., Fletcher, S., Cummings, C., Lawrence, H. R., Beato, F., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3399 · Cited by 81
Inactivation of tumor suppressor gene pten in early and advanced gallbladder cancer
Roa, I., de Toro, G., Fernández, F., Game, A., Muñoz, S., de Aretxabala, X., & Javle, M. (2015) · Diagnostic Pathology · doi:10.1186/s13000-015-0381-2 · Cited by 22
“interacting with proteins that regulate apoptosis [17].”
Metadata
- Authors
- Ocana, A., Vera-Badillo, F., Al-Mubarak, M., Templeton, A. J., Corrales-Sanchez, V., Diez-Gonzalez, L., Cuenca-Lopez, M. D., Seruga, B., Pandiella, A., & Amir, E.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-04-28
- Volume
- 9
- Issue
- 4
- Pages
- e95219
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2071591166
- Cited by
- 167
- References
- 38
- FWCI
- 1.35
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.